NouvNeu004
Multiple System Atrophy (MSA-P)
Phase 1/3Phase I/III trial approved in China; Phase I and 'special exemption' approved by FDA
Key Facts
Indication
Multiple System Atrophy (MSA-P)
Phase
Phase 1/3
Status
Phase I/III trial approved in China; Phase I and 'special exemption' approved by FDA
Company
About iRegene Therapeutics
A biotech company developing iPSC-based cell therapies for neurological and retinal diseases using an AI-integrated discovery platform.
View full company profile